Leukemia & Lymphoma Society

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR:registered:, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers. BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others. BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.

Dimericon Therapeutics is a biotech company that focuses on exploring crosslinked helix dimers and templates for molecule development.

Immune-Onc Therapeutics, Inc. is a biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic treatments, particularly aiming to create therapeutic antibodies for cancer. Immune-Onc Therapeutics leverages scientific insights related to the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics. By targeting myeloid cells, it aims to disarm immune suppression within tumors, facilitating new immunomodulatory approaches for cancer treatment. The company's focus on advancing novel immuno-oncology products positions it to provide effective new treatment options for cancer patients.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Abintus Bio, Inc. is a preclinical stage gene therapy company founded in 2020 and headquartered in Encinitas, California. The company specializes in in vivo immune cell reprogramming, developing innovative products that modulate immune cells within their native environment. By leveraging proprietary vectors and related technologies, Abintus Bio aims to enhance patient outcomes and access through its portfolio of first-in-class product candidates. These therapies are designed to directly empower patients' immune cells, enabling them to better combat diseases from within their own bodies.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Forty Seven, Inc. is a clinical-stage immuno-oncology company headquartered in Menlo Park, California, focused on developing innovative therapies to activate macrophages for cancer treatment. The company’s lead product, magrolimab, is a humanized monoclonal antibody targeting the CD47 receptor, which tumors exploit to evade immune detection. Magrolimab is currently undergoing Phase 1b/2 clinical trials for various cancers, including solid tumors and hematologic malignancies such as acute myeloid leukemia and non-Hodgkin's lymphoma. Additionally, Forty Seven is advancing other antibody-based therapies, including FSI-189, which targets SIRPa, and FSI-174, an anti-cKIT antibody. The company collaborates with Genentech and Acerta Pharma to explore further applications of its therapies in combination with other cancer treatments. Founded in 2014 and previously known as CD47 Sciences, Inc., Forty Seven operates as a subsidiary of Gilead Sciences, Inc.

Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology.

OncoPep, Inc. is an innovative biotechnology company based in North Andover, Massachusetts, founded in 2010 to develop targeted immunotherapeutics for cancer treatment. The company specializes in creating therapeutic cancer vaccines aimed at stimulating the immune system to combat various malignancies, particularly multiple myeloma. Its lead product, PVX-410, is a multi-peptide vaccine specifically designed to target antigens present on multiple myeloma cells, especially in patients with smoldering multiple myeloma, a precursor to this disease. OncoPep's proprietary technology, developed in collaboration with Dr. Kenneth Anderson at the Dana Farber Cancer Institute, utilizes a distinctive combination of peptides and adjuvants to enhance immune response against cancer. In addition to multiple myeloma, the company is exploring its peptide portfolio for applications in treating triple-negative breast cancer and various solid tumors, including breast, colon, pancreatic, and prostate cancers.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.